Overview

Sugammadex and Neostigmine at Shallow Neuromuscular Blockade

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This study is designed to compare recovery times after reversal of a residual neuromuscular block (TOF-ratio 0.5) with different doses of either neostigmine or sugammadex.
Phase:
Phase 4
Details
Lead Sponsor:
Technische Universität München
Treatments:
Neostigmine